Study Evaluating Safety, Tolerability and Pharmacokinetics (PK) of Tarlatamab in Adults With Small Cell Lung Cancer (SCLC)

NCT03319940 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

269

Enrollment

INDUSTRY

Sponsor class

Conditions

Small Cell Lung Carcinoma

Interventions

DRUG: Tarlatamab
DRUG: Pembrolizumab
DRUG: CRS Mitigation Strategies

Sponsor

Amgen